The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Guidance
Our Guidance explains the laws and regulations governing the development, manufacturing, marketing, and supply of therapeutic goods in Australia.
We recently introduced new features to improve your experience using Guidance on our website.
Loading...
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
- (-) Shortages (3)
- Advanced therapies (2)
- Advertising (35)
- Advisory bodies and committees (2)
- Artificial Intelligence (AI) (3)
- Assessed listed medicines (23)
- Australian Register of Therapeutic Goods (ARTG) (31)
- Biological medicines (22)
- Blood and blood components (10)
- Breast implant hub (1)
- Clinical trials (5)
- Complementary medicines (31)
- Cosmetics (4)
- COVID-19 (9)
- Disinfectants/Sterilants (5)
- Fees and payments (3)
- Import and export (8)
- In Vitro Diagnostic medical devices (IVDs) (41)
- Labelling and packaging (25)
- Legislation (8)
- Listed medicines (24)
- Manufacturing (40)
- Medical devices safety (24)
- Medicinal cannabis hub (4)
- Medicine safety (8)
- Metal-on-metal hip replacement implants hub (1)
- Non-prescription medicines (48)
- Over the counter (OTC) medicines (35)
- Prescription medicines (47)
- Registered complementary medicines (15)
- Regulatory compliance (27)
- Safety (15)
- Scheduling (national classification system) (5)
- Sunscreens (1)
- TGA conformity assessment certification (7)
- Therapeutic goods regulation (30)
- Unique Device Identification (UDI) hub (2)
- Vaping hub (4)
- Weight loss products (1)
Search
3 result(s) found, displaying 1 to 3
-
GuidanceGuidance for supplying substitute medicines when registered medicines are unavailable or in short supply.
-
GuidanceGuidance on the mandatory requirements for reporting current and anticipated reportable medicine shortages and discontinuations in Australia.
-
GuidanceGuidance on the mandatory reporting scheme for medicine shortages and permanent discontinuations, and our approach to compliance.